Bentham Science Logo

Track Your Manuscript:


Current Cancer Drug Targets

Volume 20, 11 Issues, 2020
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access

In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research

Contents

Current Cancer Drug Targets, Volume 12 - Number 1




Presence of Intratumoral Stem Cells in Breast Cancer Patients with or without BRCA Germline Mutations

, 12(1): 44 - 50

C. F. Singer, P. Zabkova, C. Rappaport, D. Muhr, G. Pfeiler, D. Gschwantler-Kaulich, A. Fink-Retter, C. Staudigl, I. Walter, G. Hudelist, A.-C. Spiess and E. Kubista


DOI: 10.2174/156800912798888938


The Hsp32 Inhibitors SMA-ZnPP and PEG-ZnPP Exert Major Growth-Inhibitory Effects on CD34+/CD38+ and CD34+/CD38- AML Progenitor Cells

, 12(1): 51 - 63

H. Herrmann, M. Kneidinger, S. Cerny-Reiterer, T. Rulicke, M. Willmann, K. V. Gleixner, K. Blatt, G. Hormann, B. Peter, P. Samorapoompichit, W. Pickl, G. Y. Bharate, M. Mayerhofer, W. R. Sperr, H. Maeda and P. Valent


DOI: 10.2174/156800912798888992





Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
View Full Editorial Board

COPE Compliant

Journal History

Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.75

Advertisement

New Year Offer 2021Covid Resource Center

Related Journals

Related eBooks

eBooks Catalog